everyone financial company's to and quarter of third XXXX Thank Chuck, you, results welcome update. business and the
to yesterday. in texting start, their call I due themselves we today's difficulties technical the we everyone for call, hosting available conference Before since would thank like some making for provider reschedule had to to call
support the inconvenience. Protalix. apologize for always, appreciate time So as of we we your And and
overview During and progress corporate of this the our on program an key call, will clinical developments. provide I
for the company's Officer, Mr. open Financial Rubin, financial the our review we remarks, will my Chief Following results, before questions. lines Eyal
the months. lot last a over accomplished have We several
XXXX. and development announced we our BLA line our together and BRIGHT last program Rare this help data Chiesi quarter PRX-XXX clinical and FDA PHASE-III continue and study, The that in expanded Fabry will Global XX, of the patient expect US date cutoff filing have with top this to XXXX. Diseases, disease, of first of treatment study completed to our launched the the commercialization January us from access We, we set. in Importantly, and partner set data a in indeed, for accepted report
regain York September achieving early we Fabry undeserved the and compliant productive the market an to Bank $XX Securities progress the exchange advancing pipeline into genetic in stock highly offering a disorder, October. was for in Finally, it New program such of million as in Clearly, of disease. programs quarter entry announced equity America and treatment a our in our commitment the with
recent our review detail. me let Now, highlights in more
process, that [ph] that's the filing meeting to and has the of BRRE facility set manufacturing FDA have lead fighting A meeting protein anticipate In both FDA candidate on FDA our of FDA France. May FDA it the FDA XXXX, under Chiesi, the of XX, of ours for field are the Israeli accepted a resolution BLA Israel inspection we for the travel We and as it our action FDA a of part US advised the PRX-XXX, that Our to therapeutic be inspect of this a or in BLA January the third-party PDUFA perform to advised seek an XXXX, of Type and Europe to [ph] in inspections facility is this process response have two [ph] the the the we, these who do Rare date with will candidate issue alfa, submitted restriction, that filing the committee the accelerated prior manufacturing the facilities, is Diseases pre-license an nature related hold the them currently the first and PDUFA week November, the approval pegunigalsidase FDA of advisory Fabry cooperation request has in of the of announced together we, active in indicated finished have partner discuss will year, treatment disease. has which date. also the be communication treatment pandemic, The Therefore, to priority-review is defined, Global the COVID-XX of with a unable August put to In August it study. the daily the pathway. completion The Chiese, In FDA XXXX, out submitted pegunigalsidase. to an with announced with as designation. request communication period BLA application. Chiesi this not that may FDA they granted in of in XXXX. planning dialogue of for the the to III to BRIGHT Phase of in the together Due to
PRX of first our and developing XXXX. program, of XX We collaboration designed milligrams of release per our a Fabry clinicians half four between results study, interim been BRIGHT that announced I'm in treated to patient, grateful we the replacement III trial spite trial main the head-to-head to analysis XXXX. quarter Two disease, XXX such and this for teams, results with an in of dedicated for the anticipate by the COVID-XX. of from of safety Phase challenges is in administered study, Replagal. the every and Phase follows PRX-XXX called second enzyme clinical study assess so great weeks year. infusion for switch-over previously patients The our study, to patients all first or study from an of We BALANCE The studies earlier May BRIDGE open-label study III this intravenous pharmacokinetics Fabrazyme have have and the efficacy kilogram, of expect who and Fabry PRX-XXX. the therapy the with the weeks results XX-month BRIGHT the positive as the in in study,
all the the September is early EAP alternative of October, expanded available Exchange set allows or Chiesi treating On This no in regained an FDA-approved We patients treatment the announce PRX-XXX. removed The notification of alfa EAP, Protalix or Fabry diagnosis Stock New the Protalix those therapies New of satisfactory their Stock guide. Exchange EAP with to options the have on in of are pleased was listing that Fabry III a patients received from access Pegunigalsidase -- and we in with In compliance access American for the launch [ph] standards website. the Stock who, Exchange, to program. New York disease. comparable the for X, September open non-compliant York group York Exchange from XX or physicians States with clinical program, to disease, that continued Stock early physicians, opinions part currently of list has beyond New American the our Protalix in insurers United Phase of announced American Company and broader York of forth
program of agreement that phase the other XXXX, development share balance move America continue structure agreement the We to More terms this the patients in for the market details eligible regarding capital arrangements time, offering and provide have on greater forth time conditions as on website. focus many and execute program and to $XX [ph]. development. in at aggregate enables ability met be to are commercial capital opportunity prepare entered financing would we the of at company of This access to October, we million to to and upto America forward. thrilled of as at I our clinicaltrials.gov In to equities early sheet from Securities to with us And -- Bank our necessary provides possible. launch agreement set important early Bank agent; with equity ensure commercialization to viewed for we raise, for this option can therapy to finally, like as potential save in resources this this our an
positive. Before collaborations in to is with an focused I Eyal on the continues would and to times for call and tireless in Israel these easy and The like stay their during challenging it our turn businesses I and lives again globally, all we efforts the over update XXXX. to professionalism, not impact know financials, pandemic thank employees our and once to
well a for of turn With Eyal, we financials. to team, we the We much of overview call operate very that, over our encouraged Eyal very continuing are us. and please. about the as exciting ahead an period to are now
